share_log

StockNews.com Upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold

StockNews.com Upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold

證可新聞升級詞典製藥 (NASDAQ: LXRX) 以持有
Defense World ·  2022/12/17 02:01

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Thursday.

在週四發佈的一份研究報告中，斯托克新聞網的研究分析師將Licion PharmPharmticals(納斯達克代碼：LXRX-GET)的評級從賣出上調為持有。

Lexicon Pharmaceuticals Stock Performance

Licion製藥股表現

Shares of Lexicon Pharmaceuticals stock opened at $2.08 on Thursday. The business's fifty day simple moving average is $2.14 and its 200 day simple moving average is $2.37. The firm has a market capitalization of $392.55 million, a P/E ratio of -3.35 and a beta of 1.34. Lexicon Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $4.72. The company has a current ratio of 7.54, a quick ratio of 7.54 and a debt-to-equity ratio of 0.17.

Licion PharmPharmticals的股票週四開盤報2.08美元。該業務的50日簡單移動均線切入位為2.14美元，200日簡單移動均線切入位為2.37美元。該公司的市值為3.9255億美元，本益比為-3.35，貝塔係數為1.34。Licion PharmPharmticals的12個月低點為1.31美元，12個月高位為4.72美元。該公司的流動比率為7.54，速動比率為7.54，債務權益比率為0.17。

Get
到達
Lexicon Pharmaceuticals
詞典制藥公司
alerts:
警報：

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The business had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative return on equity of 92.19% and a negative net margin of 77,648.80%. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -0.6 EPS for the current year.

Licion PharmPharmticals(納斯達克代碼：LXRX-GET Rating)最近一次發佈季度收益報告是在11月9日星期三。這家生物製藥公司公佈了該季度每股收益(0.13美元)，比分析師普遍預測的(0.15美元)高出0.02美元。該業務本季度的收入為40萬美元。Licion製藥公司的淨資產回報率為負92.19%，淨利潤率為負77648.80%。分析師預計，作為一個整體，Licion製藥公司本年度的每股收益將為-0.6%。

Institutional Trading of Lexicon Pharmaceuticals

Licion製藥的機構性交易

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of Lexicon Pharmaceuticals by 13.4% in the third quarter. Bank of New York Mellon Corp now owns 291,660 shares of the biopharmaceutical company's stock valued at $699,000 after buying an additional 34,564 shares during the period. California State Teachers Retirement System raised its stake in shares of Lexicon Pharmaceuticals by 18.3% in the third quarter. California State Teachers Retirement System now owns 96,060 shares of the biopharmaceutical company's stock valued at $231,000 after buying an additional 14,835 shares during the period. CIBC Private Wealth Group LLC purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter valued at $72,000. Alliancebernstein L.P. grew its position in shares of Lexicon Pharmaceuticals by 50.2% in the third quarter. Alliancebernstein L.P. now owns 85,011 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 28,400 shares in the last quarter. Finally, State Street Corp grew its position in shares of Lexicon Pharmaceuticals by 8.3% in the third quarter. State Street Corp now owns 1,463,569 shares of the biopharmaceutical company's stock valued at $3,513,000 after purchasing an additional 111,568 shares in the last quarter.
幾家對沖基金最近對他們在該公司的頭寸進行了調整。紐約梅隆銀行(Bank Of New York Mellon Corp)第三季度增持Licion PharmPharmticals股票13.4%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有291,660股這家生物製藥公司的股票，價值699,000美元，在此期間又購買了34,564股。加利福尼亞州教師退休系統在第三季度將其在Licion PharmPharmticals的股份增加了18.3%。加利福尼亞州教師退休系統現在擁有這家生物製藥公司96,060股股票，價值231,000美元，在此期間又購買了14,835股。加拿大帝國商業銀行私人財富集團有限責任公司在第三季度購買了價值72,000美元的Licion製藥公司的新股票頭寸。聯合伯恩斯坦公司第三季度將其在Licion PharmPharmticals的股票頭寸增加了50.2%。聯合伯恩斯坦公司現在擁有85,011股這家生物製藥公司的股票，價值20.4萬美元，在上個季度又購買了28,400股。最後，道富集團在第三季度將其在Licion PharmPharmticals的股票頭寸增加了8.3%。道富集團目前持有這家生物製藥公司1,463,569股股票，價值3,513,000美元，此前該公司在上個季度又購買了111,568股。

About Lexicon Pharmaceuticals

關於Licion製藥公司

(Get Rating)

(獲取評級)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.

Licion製藥公司是一家生物製藥公司，專注於藥品的發現、開發和商業化。該公司正在開發的口服小分子藥物候選藥物包括用於治療心力衰竭和1型糖尿病的已完成第三階段臨床試驗的索他利氟秦；以及用於治療神經病理性疼痛的LX9211。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • This is no Time to Buy Lennar but the Time is Coming
  • Game-Changing News For Mullen Automotive
  • 免費獲取StockNews.com關於Licion PharmPharmticals(LXRX)的研究報告
  • 哪兩家藍籌科技公司提高了他們的指引？
  • 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
  • 拖拉機庫存能否突破杯柄收購點？
  • 現在不是購買Lennar的時候，但時機即將到來
  • 馬倫汽車公司改變遊戲規則的消息

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接受Licion PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Licion製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論